IVQ receives award from Singapore government IP office
Appendix 4C – Quarterly Report and Business Update Investor Call
L-R: Dr Benjamin Seet, Executive Director of the Biomedical Research Council, A*STAR; His Excellency Bruce Gosper, the Australian High Commissioner to Singapore; Dr Steven Fang, Chief Executive Officer / Founder, Invitrocue Ltd; The Hon Martin Hamilton Smith, Minister for Trade and Investment, South Australian Government; Dr Raj Thampuran, Managing Director, A*STAR; Professor Ng Huck Hui, […]
July 03, 2017 – Invitrocue Limited (ASX:IVQ), a leading healthcare bio-analytic solutions providers, is pleased to announce that it has been granted Human Research Ethics Committee approval to understand a cancer research study with Sydney’s Garvan Institute of Medical Research, to provide further clinical validation of Invitrocue technology for use in personalised real-time screening of […]
Proposed Issue of Securities
Corporate Governance Statement and is accessible at the Corporate Governance Page.
22 May, 2017 – Invitrocue (ASX:IVQ) announced today that it will be expanding its cell-based assaying business into skin and wound healing. Invitrocue will develop robust and easy-to-use in vitro assays to assess the safety and effectiveness of consumer antiseptics and over-the-counter (OTC) wound dressing products. Invitrocue has signed a Master Services Agreement with Mundipharma […]
Response to ASX Appendix 4C Query
Appendix 4C – Quarterly report for entities subjected to Listing Rule 4.7B: Download here.